Table 1:
| Baseline | Follow-up | p-value | |
| ACQ (IQR) | 3.4 (2.5-4.1) | 2.8 (1.9-4.0) | 0.0001 |
| Juniper-AQLQ total-score (IQR) | 3.0 (2.5-3.9) | 3.7 (2.8-5.1) | 0.0001 |
| ≥1 GP/AE visits past year (%) | 201 (88) | 152 (66) | 0.0001 |
| ≥1 hosp admissions past year (%) | 131 (48) | 90 (33) | 0.0005 |
| ≥1 oral steroid course past year (%) | 217 (91) | 185 (77) | 0.0001 |
| Steroid courses past year (IQR) | 6 (3-8) | 3 (1-5) | 0.0001 |
| On maintenance oral steroid (%) | 119 (41) | 123 (43 | ns |
| Oral steroid dose (IQR) | 15 (10-20) | 10 (8-20) | 0.003 |
| Anti-IgE-therapy (%) | 13 (5) | 39 (14) | 0.0002 |
| Steroid-sparing agent (%) | 10 (4) | 27 (10) | 0.006 |